B-cell type acute leukaemia – Life with Disease

Go back

B-cell type acute leukaemia, also known as B-cell acute lymphoblastic leukemia (B-ALL), is a rare blood cancer that starts in the bone marrow and develops rapidly. While it primarily affects young children, adults can also be diagnosed with this disease. Understanding how B-ALL may progress and affect daily life helps patients and families navigate treatment decisions, including participation in clinical trials that may offer new hope.

Prognosis

When someone is diagnosed with B-cell type acute leukaemia, one of the first questions that naturally comes to mind is what the future might look like. The outlook for B-ALL varies significantly depending on the age of the person affected. This difference in outcomes between children and adults is one of the most striking features of this disease, and it’s important to understand these distinctions with sensitivity and realism.[2]

For children diagnosed with B-ALL, the news is generally quite encouraging. Around 85% of children with this disease remain cancer-free after five years, which doctors use as an important milestone in cancer care. The five-year survival rate for children exceeds 90%, which means that with appropriate treatment, the vast majority of young patients can expect to recover and go on to live full lives. This remarkable success in treating childhood B-ALL represents one of the major achievements in modern cancer medicine.[2]

The picture looks different for adults, particularly those over the age of 20. The five-year survival rate for adults with B-ALL sits at around 40%, which is considerably lower than for children. This doesn’t mean that adults cannot recover from B-ALL, but it does indicate that the disease tends to be more challenging to treat successfully in older patients. The reasons for this difference are complex and relate to how the disease behaves differently in adult bodies compared to children’s bodies, as well as how adults tolerate intensive treatments.[2][5]

It’s worth noting that B-ALL is considered a serious condition that requires prompt attention. The word acute in the disease name refers to how quickly the disease develops and progresses, often over days or weeks rather than months or years. This rapid progression means that people with B-ALL usually need to start treatment quite soon after diagnosis. However, the same rapid nature of the disease also means it often responds well to treatment when therapy is started promptly.[3][6]

Several factors influence an individual’s prognosis beyond just age. One of the strongest indicators of how well someone will respond to treatment is something called measurable residual disease, or MRD. This refers to small amounts of cancer cells that might remain in the body after initial treatment, even when they can’t be seen under a regular microscope. People who achieve very low or undetectable MRD levels after treatment tend to have better outcomes than those who still have detectable disease.[17]

Certain genetic features of the leukaemia cells themselves also affect prognosis. For example, some people have a genetic change called the Philadelphia chromosome, which affects between 20 and 30 out of every 100 people with ALL. Historically, having this genetic change meant a more difficult treatment course, though newer targeted therapies have improved outcomes considerably for these patients.[3]

Natural Progression

Understanding how B-cell type acute leukaemia develops and spreads without treatment helps explain why prompt medical attention is so important. The disease begins deep inside the bones, in the bone marrow, which is the soft, spongy tissue in the center of bones where the body produces blood cells. In B-ALL, something goes wrong with the production of B-cells, which are normally an important type of white blood cell that helps fight infections.[2]

In a healthy person, bone marrow produces B-cells in a controlled, orderly manner. These cells mature through several stages before becoming fully functional infection-fighting cells. In B-ALL, the bone marrow starts producing too many abnormal, immature B-cells called lymphoblasts. These immature cells don’t work properly—they can’t fight infections the way healthy B-cells do. Instead, they just keep multiplying rapidly, crowding out the production of normal blood cells.[2][13]

As these abnormal cells accumulate in the bone marrow, they begin to interfere with the production of other essential blood components. The bone marrow struggles to make enough healthy red blood cells, which carry oxygen throughout the body. It can’t produce adequate numbers of normal white blood cells to fight infections. And it fails to make sufficient platelets, the tiny cell fragments responsible for blood clotting. This explains why people with untreated B-ALL often feel extremely tired, get frequent infections, and bruise or bleed easily.[5]

The disease doesn’t stay confined to the bone marrow. Once the abnormal B-cells build up to high enough levels, they spill over into the bloodstream. The blood carries these cancerous cells throughout the entire body, allowing them to spread to other organs and tissues. This is why B-ALL is considered a systemic disease—it affects the whole body, not just one localized area.[2]

Common sites where B-ALL cells tend to accumulate outside the bone marrow include the lymph nodes, small bean-shaped organs throughout the body that are part of the immune system. As leukaemia cells collect in lymph nodes, these organs swell, sometimes becoming visible or palpable, particularly in the neck, armpits, or groin. The liver and spleen, two large organs in the abdomen, may also become enlarged as they fill with leukaemia cells. This enlargement can cause discomfort or a feeling of fullness in the belly.[2][13]

In some cases, B-ALL spreads to the central nervous system, meaning the brain and spinal cord. This can lead to neurological symptoms that we’ll discuss in the complications section. Less commonly, the disease may spread to the testicles in males, though this is considered rare.[2][13]

Without treatment, the rapid accumulation of leukaemia cells and the suppression of normal blood cell production would continue to worsen. The person would become increasingly vulnerable to serious infections because of insufficient healthy white blood cells. Severe anemia from lack of red blood cells would cause profound weakness and organ damage from oxygen deprivation. Insufficient platelets would lead to dangerous bleeding. This is why B-ALL, despite its name referencing “acute” or sudden onset, actually represents a medical emergency requiring swift intervention.[11]

Possible Complications

B-cell type acute leukaemia can lead to various complications, both from the disease itself and, in some cases, from the intensive treatments required to combat it. Understanding these potential complications helps patients and families prepare and recognize warning signs that require immediate medical attention.

One of the most serious complications occurs when leukaemia cells spread to the brain and spinal cord, collectively known as the central nervous system. This spread can cause a range of neurological problems. People may experience persistent headaches that don’t respond well to typical pain relievers. Nausea and vomiting may occur, sometimes quite severe. Vision problems can develop, including blurred vision or seeing double. Some people experience balance problems or difficulty coordinating their movements. In severe cases, facial muscle weakness or numbness may appear, or seizures may occur.[5][16]

The enlargement of internal organs represents another category of complications. As mentioned earlier, the liver and spleen can become significantly enlarged as they fill with leukaemia cells. A greatly enlarged spleen can cause pain or discomfort in the upper left part of the abdomen. An enlarged liver may cause similar discomfort on the right side. These enlarged organs can also affect digestion and appetite, contributing to weight loss and nutritional problems.[5][16]

A rare but serious complication is something called Superior Vena Cava syndrome, or SVC syndrome. This occurs when leukaemia cells or swollen lymph nodes compress a large vein called the superior vena cava, which carries blood from the upper body back to the heart. When this vein is compressed, blood flow is obstructed, potentially causing swelling of the face, neck, and arms, along with difficulty breathing. This is considered a medical emergency requiring immediate treatment.[5][16]

The suppression of normal blood cell production leads to complications of its own. With too few healthy white blood cells, patients become vulnerable to frequent and potentially severe infections. These infections can affect any part of the body but commonly involve the lungs, urinary tract, or skin. Fever often signals an infection in someone with B-ALL, and any fever in a person with this disease should be reported to a doctor promptly, as infections can quickly become life-threatening when the immune system is compromised.[2][13]

Low platelet counts create bleeding complications. People may experience frequent nosebleeds that are difficult to stop. The gums may bleed easily when brushing teeth. Small, red, pinpoint spots called petechiae may appear on the skin, representing tiny areas of bleeding under the skin surface. Larger bruises may develop from even minor bumps or injuries. In severe cases, internal bleeding can occur, which is particularly dangerous if it affects the brain or gastrointestinal tract.[5][8]

Severe anemia from lack of red blood cells causes complications related to insufficient oxygen delivery throughout the body. People may feel extremely weak and fatigued, unable to perform even simple daily activities. Shortness of breath may occur with minimal exertion or even at rest. The heart may beat faster than normal as it tries to compensate for low oxygen levels. Prolonged severe anemia can strain the heart and other organs.[6]

⚠️ Important
Any fever, unusual bleeding that won’t stop, severe headache, vision changes, difficulty breathing, or signs of infection should be reported to your healthcare team immediately. Early recognition and treatment of complications can prevent them from becoming more serious and potentially life-threatening.

Impact on Daily Life

B-cell type acute leukaemia affects virtually every aspect of daily life, creating challenges that extend far beyond the physical symptoms of the disease. Understanding these impacts helps patients and families develop strategies to cope and maintain the best possible quality of life during treatment and recovery.

The physical impact of B-ALL can be profound. Extreme fatigue is one of the most common and debilitating symptoms that people with this disease experience. This isn’t the normal tiredness that improves with rest—it’s a deep, overwhelming exhaustion that can make even simple tasks like getting dressed, preparing a meal, or taking a shower feel impossibly difficult. Many people find they need to rest frequently throughout the day and may spend much of their time in bed or on the couch.[5][6]

Pain in the bones and joints affects many people with B-ALL. This pain can range from a dull ache to sharp, severe discomfort that interferes with movement and sleep. Children with B-ALL may develop a limp or stop participating in activities they previously enjoyed. Adults may find it difficult to work, exercise, or perform household tasks. Managing this pain becomes an important part of daily life.[2][13]

The increased vulnerability to infections means that people with B-ALL need to be careful about their exposure to germs. During treatment, doctors may recommend avoiding crowded places, staying away from people who are sick, and practicing careful hand hygiene. This can mean missing out on social gatherings, school events, work functions, or community activities. The isolation this creates can be emotionally difficult, particularly when it continues for months.[21]

Dietary challenges often arise with B-ALL. Loss of appetite, changes in taste, nausea, and mouth sores can make eating difficult and unpleasant. Some people may need to follow special food safety guidelines to reduce infection risk, which can mean avoiding certain foods they enjoy. Weight loss or weight gain from treatments like steroids can affect body image and self-esteem. After stem cell transplant or CAR T-cell therapy, dietary restrictions may continue for months to protect against food-borne infections.[21]

Work and school attendance typically becomes impossible during intensive treatment phases. The disease itself, along with the side effects of treatment, usually makes it impractical to maintain normal work or school schedules. Children may need home-based tutoring or special educational accommodations. Adults may need extended medical leave, which can create financial stress and career concerns. Even after completing initial treatment, fatigue and other lingering effects may make returning to full-time activities difficult.[22]

Exercise and physical activity require modification. While gentle activity can actually help with fatigue and improve overall wellbeing, people with B-ALL need to listen to their bodies and not push too hard. Starting with gentle walking and gradually building up activity as tolerated is often recommended. However, during periods when blood counts are particularly low, even light exercise may need to be avoided. Physical therapists can help develop appropriate exercise plans that balance activity with rest.[21]

The emotional and psychological impact of B-ALL affects both patients and their families. Anxiety about the disease, its treatment, and its outcome is completely normal and very common. Fear of recurrence may persist even after successful treatment. Depression can develop, partly due to the stress of the illness and partly from the physical effects of the disease and treatments on brain chemistry. Many people benefit from counseling or support groups to help process these complex emotions.[23]

Social relationships may change during and after B-ALL treatment. Friends and family members may not know how to react or what to say, sometimes leading to awkwardness or distance. The patient’s own personality or mood may change due to the stress of illness or the effects of medications like steroids. Children and teenagers may feel different from their peers, affecting their social development and self-image. Maintaining connections with supportive people becomes especially important during this challenging time.[22]

Financial concerns add another layer of stress to daily life with B-ALL. Treatment for this disease is intensive and expensive, even with health insurance. Many families face medical bills, increased costs for transportation to medical appointments, and lost income if a parent or the patient themselves must stop working. These financial pressures can create significant anxiety and may affect treatment decisions and quality of life.[23]

Despite these challenges, many people find ways to adapt and maintain meaning and joy in their lives. Small adjustments can make daily activities more manageable. Planning activities during times of day when energy is highest, accepting help from others, using assistive devices when needed, and setting realistic expectations all help people cope. Focusing on what can be controlled rather than what cannot, maintaining social connections in whatever ways are possible, and finding moments of pleasure and normalcy within each day help preserve quality of life.[21]

Support for Family

Families play a crucial role in supporting someone with B-cell type acute leukaemia, including helping them explore and participate in clinical trials. Understanding what clinical trials are, how they work, and how to support a loved one through this process can make a significant difference in the patient’s journey.

Clinical trials are research studies that test new ways to prevent, detect, or treat diseases like B-ALL. When someone participates in a clinical trial for B-ALL, they might receive a new medication, a new combination of existing medications, a new type of therapy like immunotherapy, or a new approach to using established treatments. These trials are carefully designed and monitored to evaluate whether new treatments are safe and effective.[10]

For people with B-ALL, clinical trials can offer several potential benefits. They may provide access to new treatments that aren’t yet available outside of research settings. For patients whose disease hasn’t responded well to standard treatments, clinical trials might offer additional options when few others remain. Even if the treatment being studied doesn’t help the individual patient, participation in trials contributes valuable information that advances medical knowledge and may help future patients.[10]

Families can help their loved one explore clinical trial options in several practical ways. Start by having open conversations with the patient’s healthcare team about whether clinical trials might be appropriate. Doctors can provide information about trials specifically designed for B-ALL and can explain whether the patient’s specific situation makes them eligible for particular studies. Healthcare teams can also help families understand the potential benefits and risks of trial participation.[10]

Researching available clinical trials is another way families can help. Several online databases list current clinical trials for B-ALL, including resources provided by cancer organizations and government health agencies. Family members can help search these databases, organize information about different trials, and prepare questions to ask doctors about specific studies. This research can feel overwhelming, so breaking it into smaller tasks and involving multiple family members can make it more manageable.

Understanding eligibility criteria is important when considering clinical trials. Each trial has specific requirements about who can participate, based on factors like age, disease stage, previous treatments received, and overall health status. Families can help gather the medical records and test results needed to determine whether their loved one meets these criteria. Keep organized files with all medical information, as this documentation will be needed when applying to trials.

The practical aspects of clinical trial participation often require family support. Many trials take place at specialized cancer centers that may be far from home. Family members can help research travel options, arrange transportation, and plan accommodations if the patient needs to stay near the treatment center for extended periods. Some clinical trials and cancer organizations offer assistance with travel expenses, and families can help investigate and apply for these resources.

Emotional support during clinical trial participation is equally important. Making the decision to join a clinical trial can be stressful, as it involves uncertainty about outcomes and often requires additional time commitments for appointments, tests, and monitoring. Family members can provide reassurance, attend appointments with the patient to help ask questions and remember information, and offer encouragement throughout the process. Simply being present and listening when the patient wants to talk about their hopes, fears, or experiences can provide valuable support.

Helping with daily logistics frees up the patient’s energy for focusing on treatment. This might include preparing meals that meet any dietary requirements, managing household responsibilities, coordinating care for other family members, keeping track of appointment schedules, organizing medications, and maintaining communication with the wider circle of family and friends who want updates.

Families should also recognize that clinical trial participation is always voluntary. If a patient decides a particular trial isn’t right for them, or chooses to withdraw from a trial they’ve started, this decision should be respected and supported. Healthcare teams will have alternative treatment options available, and there’s no penalty for declining or leaving a clinical trial.

⚠️ Important
Taking care of a family member with B-ALL is demanding, and caregivers need support too. Don’t hesitate to ask for help from other family members, friends, or community resources. Many cancer centers offer support services specifically for caregivers, including counseling, support groups, and educational programs. Taking care of yourself enables you to provide better care for your loved one.

Remember that every person’s experience with B-ALL and clinical trials is unique. What works for one family may not work for another. Stay flexible, communicate openly with each other and with the healthcare team, and focus on providing the specific types of support that your loved one finds most helpful. Your involvement and support can make a meaningful difference in their journey through treatment and recovery.

💊 Registered drugs used for this disease

List of officially registered medicines that are used in the treatment of this condition, based only on the provided sources:

  • Imatinib – A targeted cancer drug used to treat Philadelphia chromosome-positive acute lymphoblastic leukemia by blocking abnormal proteins that encourage leukaemia cell growth
  • Dasatinib – A tyrosine kinase inhibitor used in front-line treatment of Philadelphia-positive B-ALL, often used to reduce the intensity of chemotherapy needed
  • Ponatinib – A tyrosine kinase inhibitor used in treatment protocols for Philadelphia-positive B-ALL, showing promising results when used in sequence or combination with other therapies
  • Blinatumomab – An immunotherapy treatment used for patients with B-ALL who have detectable measurable residual disease, and increasingly being used in combination with other treatments in first-line therapy
  • Inotuzumab ozogamycin – A targeted therapy being investigated for use in addition to first-line chemotherapy for B-ALL patients
  • Tisagenlecleucel (KYMRIAH) – A CAR T-cell therapy approved for children and young adults up to 25 years of age with relapsed or refractory B-cell acute lymphoblastic leukemia

Ongoing Clinical Trials on B-cell type acute leukaemia

  • A Study to Test the Safety and How AZD4512 Works in Patients with Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia

    Recruiting

    1 1
    Investigated diseases:
    Investigated drugs:
    Spain
  • Study of chemotherapy with blinatumomab and tyrosine kinase inhibitors in newly diagnosed children and young adults with Philadelphia chromosome positive B-cell acute lymphoblastic leukemia

    Recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Austria Czechia Denmark Finland France Germany +7
  • Long-Term Follow-Up Study for Patients Treated with CAR T-Cell Therapy Using PHE885, YTB323, and Tisagenlecleucel

    Recruiting

    1 1 1 1
    Austria Belgium Denmark Finland France Germany +6
  • Study on CD19-CAR T Cells, Fludarabine, and Cyclophosphamide for Children and Young Adults with Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia

    Recruiting

    1 1 1
    Investigated diseases:
    Italy
  • Study on Pegaspargase and Rituximab for Treating Children with Acute Lymphoblastic Leukemia

    Not yet recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Croatia Greece Hungary Slovenia
  • Study of UCART22 for Patients with Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia

    Not yet recruiting

    1 1 1
    Investigated diseases:
    France Italy Spain
  • Study on the Safety and Effectiveness of Brexucabtagene Autoleucel for Children and Teens with Relapsed or Refractory Acute Lymphoblastic Leukemia or Non-Hodgkin Lymphoma

    Not recruiting

    1 1 1
    Investigated drugs:
    Czechia France Germany Italy Poland Spain
  • Study of SAR443579 Infusion for Adults and Children with Relapsed or Refractory Acute Myeloid Leukemia, B-Cell Acute Lymphoblastic Leukemia, HR-MDS, or BPDCN

    Not recruiting

    1 1 1
    France The Netherlands
  • Study on the Safety of Epcoritamab for Children and Young Adults with Relapsed or Refractory Aggressive B-cell Lymphomas

    Not recruiting

    1 1
    Investigated diseases:
    Investigated drugs:
    Belgium Czechia France Germany Italy Spain

References

https://cancer.osu.edu/for-patients-and-caregivers/learn-about-cancers-and-treatments/cancers-conditions-and-treatment/cancer-types/blood-cancers/leukemia/b-cell-acute-lymphoblastic-leukemia

https://leukemiarf.org/leukemia/acute-lymphoblastic-leukemia/b-cell-lymphoblastic-leukemia/

https://www.cancerresearchuk.org/about-cancer/acute-lymphoblastic-leukaemia-all/about

https://www.cancer.gov/publications/dictionaries/cancer-terms/def/b-cell-acute-lymphoblastic-leukemia

https://my.clevelandclinic.org/health/diseases/21564-acute-lymphocytic-leukemia

https://www.mayoclinic.org/diseases-conditions/acute-lymphocytic-leukemia/symptoms-causes/syc-20369077

https://www.leukaemiacare.org.uk/support-and-information/information-about-blood-cancer/blood-cancer-information/leukaemia/acute-lymphoblastic-leukaemia/b-cell-acute-lymphoblastic-leukaemia-b-cell-all/

https://www.webmd.com/cancer/lymphoma/b-cell-acute-lymphoblastic-leukemia-children

https://us.kymriah.com/acute-lymphoblastic-leukemia-children/about-b-cell-all/understanding-b-cell-all

https://www.cancer.org/cancer/types/acute-lymphocytic-leukemia/treating/typical-treatment.html

https://www.cancer.gov/types/leukemia/patient/adult-all-treatment-pdq

https://cancer.osu.edu/for-patients-and-caregivers/learn-about-cancers-and-treatments/cancers-conditions-and-treatment/cancer-types/blood-cancers/leukemia/b-cell-acute-lymphoblastic-leukemia

https://leukemiarf.org/leukemia/acute-lymphoblastic-leukemia/b-cell-lymphoblastic-leukemia/

https://www.ncbi.nlm.nih.gov/books/NBK65727/

https://www.mayoclinic.org/diseases-conditions/acute-lymphocytic-leukemia/diagnosis-treatment/drc-20369083

https://my.clevelandclinic.org/health/diseases/21564-acute-lymphocytic-leukemia

https://chi.scholasticahq.com/article/117026-how-i-treat-newly-diagnosed-acute-lymphoblastic-leukemia

https://cancer.osu.edu/for-patients-and-caregivers/learn-about-cancers-and-treatments/cancers-conditions-and-treatment/cancer-types/blood-cancers/leukemia/b-cell-acute-lymphoblastic-leukemia

https://leukemiarf.org/leukemia/acute-lymphoblastic-leukemia/b-cell-lymphoblastic-leukemia/

https://my.clevelandclinic.org/health/diseases/21564-acute-lymphocytic-leukemia

https://www.cancerresearchuk.org/about-cancer/acute-lymphoblastic-leukaemia-all/living-with/diet-exercise

https://www.kucancercenter.org/news-room/blog/2020/10/what-you-should-know-acute-lymphoblastic-leukemia

https://www.cancer.org/cancer/types/acute-lymphocytic-leukemia/after-treatment/follow-up.html

https://www.mayoclinic.org/diseases-conditions/acute-lymphocytic-leukemia/diagnosis-treatment/drc-20369083

https://medlineplus.gov/diagnostictests.html

https://www.questdiagnostics.com/

https://www.healthdirect.gov.au/diagnostic-tests

https://www.who.int/health-topics/diagnostics

https://www.nibib.nih.gov/science-education/science-topics/rapid-diagnostics

https://www.yalemedicine.org/clinical-keywords/diagnostic-testsprocedures

https://www.health.harvard.edu/diagnostic-tests-and-medical-procedures

FAQ

Can B-cell acute lymphoblastic leukemia be cured?

Yes, particularly in children. Around 85% of children with B-ALL remain cancer-free after five years, with five-year survival rates exceeding 90%. For adults over age 20, the five-year survival rate is around 40%, which is lower but still means many adults can be successfully treated.

How quickly does B-ALL progress without treatment?

B-ALL is an aggressive cancer that progresses rapidly, often over days or weeks rather than months. The word “acute” in its name refers to this fast development. This is why people diagnosed with B-ALL usually need to start treatment quite soon after diagnosis.

What causes B-cell acute lymphoblastic leukemia?

B-ALL is caused by genetic mutations (changes) in genes that regulate B-cell development. The exact cause of these mutations is unknown in most cases. Risk factors include genetic conditions like Down syndrome, previous exposure to radiation or chemotherapy, family history of leukemia, and suppressed immune systems.

Will my child be able to return to school during B-ALL treatment?

School attendance typically becomes difficult or impossible during intensive treatment phases due to the disease itself and treatment side effects. Many children need home-based tutoring or special educational accommodations during treatment. The ability to return to school depends on blood counts, infection risk, and overall health status.

What is the difference between B-cell ALL and T-cell ALL?

B-cell ALL affects B lymphocytes, which normally make antibodies to fight infection, and accounts for about 75-85% of childhood cases and 75-80% of adult cases. T-cell ALL affects T lymphocytes, which kill germs and support other immune cells, and is less common, making up around 25% of adult cases and 12-15% of childhood cases.

🎯 Key takeaways

  • B-cell acute lymphoblastic leukemia has dramatically different cure rates in children (over 90%) versus adults (around 40%), making age one of the strongest factors affecting outcomes.
  • The disease progresses rapidly—often within days or weeks—which is why it requires prompt treatment but also means it often responds well when therapy starts quickly.
  • Measurable residual disease (MRD) after treatment is one of the strongest predictors of outcome, more important than many other factors in determining long-term prognosis.
  • B-ALL starts in bone marrow but spreads throughout the body via blood, commonly affecting lymph nodes, liver, spleen, and sometimes the brain and spinal cord.
  • Extreme fatigue in B-ALL isn’t ordinary tiredness—it’s overwhelming exhaustion that doesn’t improve with rest and can make even simple daily tasks feel impossible.
  • Clinical trials for B-ALL may offer access to promising new treatments like CAR T-cell therapy, immunotherapy combinations, or targeted drugs not yet widely available.
  • Around 75% of all B-ALL cases affect children younger than six years old, making it the most common type of childhood leukemia.
  • The Philadelphia chromosome appears in 20-30% of B-ALL cases and historically meant worse outcomes, but newer targeted therapies have significantly improved results for these patients.